Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last kr0.88 DKK
Change Today +0.125 / 16.56%
Volume 3.7M
VELO On Other Exchanges
Symbol
Exchange
Copenhagen
OTC US
Frankfurt
OTC US
As of 11:03 AM 05/4/15 All times are local (Market data is delayed by at least 15 minutes).

veloxis pharmaceuticals a/s (VELO) Snapshot

Open
kr0.80
Previous Close
kr0.76
Day High
kr0.88
Day Low
kr0.79
52 Week High
07/4/14 - kr2.30
52 Week Low
04/30/15 - kr0.75
Market Cap
1.5B
Average Volume 10 Days
1.2M
EPS TTM
kr-0.02
Shares Outstanding
1.7B
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VELOXIS PHARMACEUTICALS A/S (VELO)

Related News

No related news articles were found.

veloxis pharmaceuticals a/s (VELO) Related Businessweek News

No Related Businessweek News Found

veloxis pharmaceuticals a/s (VELO) Details

Veloxis Pharmaceuticals A/S operates as a specialty pharmaceutical company. The company’s proprietary technology, MeltDose is designed to enhance the absorption and bioavailability of select orally administered drugs. Its lead product candidate is Envarsus, a once-daily dosage tablet version of tacrolimus for the treatment of kidney transplant patients. The company was formerly known as LifeCycle Pharma A/S and changed its name to Veloxis Pharmaceuticals A/S in July 2011. Veloxis Pharmaceuticals A/S is headquartered in Hørsholm, Denmark.

31 Employees
Last Reported Date: 03/3/15

veloxis pharmaceuticals a/s (VELO) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

veloxis pharmaceuticals a/s (VELO) Key Developments

Veloxis Pharmaceuticals A/S Announces Amendments to the Articles of Association in Association with Issue of Warrants

Veloxis Pharmaceuticals A/S announced that in accordance with its authorization pursuant to Section 5A of the Articles of Association, the board of directors of the company has on 27 March 2015 issued 4,748,092 warrants for the subscription of nominally DKK 474,809.20 shares in the company. The amendment of the articles of association associated with the issue of warrants has been registered with the Danish Business Authority.

Veloxis Pharmaceuticals A/S Proposes Amendments to the Articles of Association

Veloxis Pharmaceuticals A/S announced that at the AGM to be held on March 26, 2015, the shareholders will consider proposal by the board of directors for approval of updated remuneration policy including general guidelines for incentive-based remuneration to members of the board of directors and executive management and amendment of the articles of association in accordance therewith.

Veloxis Pharmaceuticals A/S Announces Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Earnings Guidance for 2015

Veloxis Pharmaceuticals A/S announced earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported revenue of DKK 3,214,000 against DKK 12,206,000 a year ago operating loss was DKK 56,331,000 against DKK 23,797,000 a year ago. Loss before tax was DKK 50,665,000 against DKK 25,222,000 a year ago. Net loss for the year was DKK 49,177,000 or DKK 0.03 per basic and diluted share against DKK 24,700,000 or DKK 0.01 per basic and diluted share a year ago. Cash outflow from operating activities was DKK 42,139,000 against DKK 47,417,000 a year ago. For the year, the company reported revenue of DKK 123,395,000 against DKK 38,148,000 a year ago. Operating loss was DKK 58,604,000 against DKK 136,135,000 a year ago. Loss before tax was DKK 37,701,000 against DKK 140,561,000 a year ago. Net loss for the year was DKK 36,319,000 or DKK 0.02 per basic and diluted share against DKK 139,311,000 or DKK 0.08 per basic and diluted share a year ago. Cash outflow from operating activities was DKK 77,243,000 against DKK 157,747,000 a year ago. For 2015, the company is expecting an operating loss of DKK 200 million- 240 million compared to the realized operating loss of DKK 59 million in 2014. Net loss is expected to be in the range of DKK 195 million- 235 million compared to the net loss of DKK 36 million in 2014. As of 31 December 2014, the company's cash position equaled DKK 270 million and the company's 31 December 2015 cash position is expected to be in the range of DKK 55 million- 95 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VELO:DC kr0.88 DKK +0.125

VELO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abzena PLC 80.50 GBp -1.50
Durect Corp $2.33 USD +0.13
Enzon Pharmaceuticals Inc $1.35 USD +0.01
Onxeo SA €5.46 EUR +0.04
Oxford Biomedica PLC 11.25 GBp 0.00
View Industry Companies
 

Industry Analysis

VELO

Industry Average

Valuation VELO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.4x
Price/Book 4.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 7.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VELOXIS PHARMACEUTICALS A/S, please visit www.veloxis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.